Retatrutide Drug Asset Due Diligence Report 2026

This Retatrutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Retatrutide can convert its Synthetic peptide profile and GCGR x GIPR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Retatrutide (query alias: retatrutide)
Modality / target	Synthetic peptide; GCGR x GIPR x GLP-1R; GCGR agonists, GIPR agonists, GLP-1R agonists
Highest global status	Phase 3
Originator	Eli Lilly & Co.
Active developers	Eli Lilly & Co.

The MCP disease footprint includes Metabolic dysfunction-associated steatotic liver disease, Diabetes Mellitus, Type 2, Obesity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07357415	Phase 3	Active, not recruiting	600	Percent Change from Baseline in Body Weight
NCT07232719	Phase 3	Active, not recruiting	250	Percent Change from Baseline in Body Weight
CTR20255050	Phase 3	进行中（招募中）	4	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Phase 3; n=537; evaluation: Positive. Reported fields: HbA1c(Efficacy estimand,from a baseline of 7.9% at 40 weeks) = -0.8 % Met; HbA1c(Efficacy estimand,from a baseline of 7.9% at 40 weeks) = -2.0 % Met; HbA1c(Efficacy estimand,from a baseline of 7.9% at 40 weeks) = -1.7 % Met

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Phase 3; n=445; evaluation: Positive. Reported fields: Body weight(change fr baseline) = -28.7 % ; Body weight(change fr baseline) = -26.4 % ; Body weight(change fr baseline) = -2.1 %

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials

Not Applicable; n=15491; evaluation: Positive. Reported fields: Weight Loss: Difference (%) = 17.8(95% CI, 16.3 - 19.3); Difference (%) = 13.9(95% CI, 11.0 - 16.7); Difference (%) = 5.8(95% CI, 3.6 - 8.0); Difference (%) = 22.1(95% CI, 19.3 - 24.9); Weight Loss: Difference (%) = 17.8(95% CI, 16.3 - 19.3); Difference (%) = 13.9(95% CI, 11.0 - 16.7); Difference (%) = 5.8(95% CI, 3.6 - 8.0); Difference (%) = 22.1(95% CI, 19.3 - 24.9); Weight Loss: Difference (%) = 17.8(95% CI, 16.3 - 19.3); Difference (%) = 13.9(95% CI, 11.0 - 16.7); Difference (%) = 5.8(95% CI, 3.6 - 8.0); Difference (%) = 22.1(95% CI, 19.3 - 24.9)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Retatrutide addresses Metabolic dysfunction-associated steatotic liver disease, Diabetes Mellitus, Type 2, Obesity. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 31 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GCGR x GIPR x GLP-1R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-09-28	信达生物与健之佳达成战略合作，共筑零售减重新篇章	Approved	Financial terms not disclosed
2025-03-24	The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist	Phase 2	US$200.0M upfront; US$1,800.0M milestones
2025-03-17	American Regent entered into an agreement to commercialize Xeris Biopharma 's Gvoke VialDx ( glucagon ) for gastrointestinal use in the United States	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of a menin inhibitor with a pyrazolopiperidine GLP-1 receptor agonist for treating diabetes and obesity”. The milestone feed surfaced a patent-application signal described as “GLP-1 receptor agonist compounds for treating a proliferative synovial disorder”. The milestone feed surfaced a patent-application signal described as “Combination of GLP-1r/GIPR dual agonist and FGF21 compound and use”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO